EGFR and neoplasm: According to the National Comprehensive Cancer Network (NCCN) guideline, all patients with metastatic CRC who are eligible for anti-epidermal growth factor receptor (EGFR) inhibitors should have the tumor tissue tested for BRAF and RAS mutations10.